Date: 2018-09-10
Type of information: Nomination
Compound: chief medical officer
Company: Medivir (Sweden)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 10, 2018, Medivir announced it has appointed Linda Basse as Chief Medical Officer effective October 1, 2018. Dr. Basse will report to CEO Christine Lind and join the Medivir Executive Team. Dr. Basse has more than 18 years of drug development and medical marketing experience, including approvals and marketing of new cancer therapies. Her previous roles include Medical Director at Zealand Pharma with responsibility for an orphan disease drug candidate and Medical Director at Genmab with responsibilities leading to the approval of daratumumab and indication expansion of ofatumumab in hematology-oncology indications. She also held the position as Medical Director at Topotarget developing drugs for cancer, along with Medical Manager and Medical Advisor roles at Abbott Laboratories, Nycomed and NovoNordisk.
- Dr. Basse holds an MD and PhD from Copenhagen University, and has done clinical research at Copenhagen University Hospital. She is also a member of the European Society of Medical Oncology and the American Society of Clinical Oncology.
Financial terms:
Latest news:
Is general: Yes
